The IL-23/IL-17 axis is a major focus of spondyloarthritis research, and many pharmaceutical companies are actively working on strategies to block IL-17 in uveitis, AS and related spondyloarthropathies [14,15,36,42]. This evidence concerns the gene IL17A and uveitis.